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Summary: The effects of the angiotensin-converting enzyme inhibitor ramipril on thirteen endocrinological tests
were evaluated. These tests comprised serum follitropin, lutropin, prolactin, thyrotropin, free thyroxine, total thyrox-
ine, free triiodothyronine, parathyrin, cortisol, testosterone, sex hormone binding globulin, androstenedione and
dehydroepiandrosterone sulphate.
Eleven hypertensive outpatients, 9 men and 2 women, treated at the department of internal medicine in Turku
University Central Hospital, received 5 mg of ramipril once a day for the study period of four weeks. The above
mentioned endocrinological tests were performed before and at the end of the ramipril treatment. Ramipril decreased
the value of free thyroxine statistically significantly, p = 0.011, from the mean value of 17.1 pmol/1 to the mean
value of 16.0 pmol/1 when measured with Amerlex-MAB* free thyroxine kit. The mean within-subject difference
was -1.10 pmol/1 with a 95% confidence interval of -1.87 0.33 pmol/1. With the AutoDELFIA™ free
thyroxine kit and with the reference method dialysis+RIA no effect was detected. Other endocrinological tests
examined were not affected by ramipril. Since the decreasing effect of ramipril on free thyroxine was detected only
with Amerlex-MAB* but neither with AutoDELFIA™ nor with dialysis+RIA, the effect was concluded to be
analytical. The underlying mechanism and the component ultimately interfering with the analysis is unknown.
Introduction ramiprilat, in the liver (8). Even though ramipril was
Drugs affect laboratory test results (1, 2). Drug effects introduced into clinical use several years ag°> little is
on laboratory tests are either biological or analytical. For laus^ *>out its effects on endocrinological tests. Only
instance, amiodarone is known to increase the value of the effects on the renm-angiotensin-aldosterone system
thyrotropin biologically (3-5) whereas several cepha- t9"11)' cortiso1' 'atecholamines, vasopressin (9) and in-
losporines are known to interfere with current methods sulin <12> have been studied ^  Present studv was car'
for measuring creatinine (6, 7). ried out to examine whether ramiPril has other endocri-
nological effects.
The interfering drug effects should be known and they
should also be recognized by clinicians in order to inter-
pret laboratory test results correctly. Since new drugs Materials and Methods
and new laboratory methods are introduced frequently, Subjects
laboratory staff should be alert and eager to actively The study population consisted of 11 patients with essential hyper-
search for drug effects on laboratory tests. For this pur- tension, 9 men and 2 women, mean age 41.3 years (range 36—49
pose, it is not ethically suitable to treat healthy volun- vears)· M subJects Save their mf°nned consent to the study. One
, , . . subject used low-dose budesonide and beclomethasone inhalations,
teers with drugs. However, related to other drug mvesti-
 others had no constant medication. All subjects had diastolic blood
gations, it is reasonable to also examine the unknown pressure between 95 and 110 mm Hg repeatedly and the mean
effects of investigational drugs on laboratory tests. This 24 h-blood Pressure in the ambulatory recording above 140/85 mm
.. . .. , . . . , . . . Hg. The patients were examined by an internist to exclude second-
applies especially to endocrinological tests, which usu- ^
 hypertension. Despite hypertension, the patients were healthy.
ally are not included in the safety tests of pharmaceutical
industry but often, however, play an important role in Study protocol
clinical diagnostics. All subjects received the angiotensin-converting enzyme inhibitor
_ , . . , . , . . . . ramipril 5 mg (Ramace® 5 mg tabl, Suomen Astra Oy, Finland)Ramipril is a long-acting angiotensin-converting enzyme
 once a for me study period of four weeks Subjects were tested
inhibitor, which is converted to its active metabolite, for serum follitropin, lutropin, prolactin, thyrotropin, free thyrox-
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ine, total thyroxine, free triiodothyronine, parathyrin, cortisol, tes-
tosterone, sex hormone binding globulin, androstenedione and de-
hydroepiandrosterone sulphate before medication and at the end of
the study period. Blood samples were taken between 7 a.m. and
9a.m. after fasting from 10p.m. the previous evening. Methods,
manufacturers and coefficients of inter-assay variation (CV%) of
the assays are displayed in table 1. The study protocol was ap-
proved by the Ethics Committee of the Turku University Central
Hospital and the study followed the recommendations for biomedi-
cal research involving human subjects according to the current ver-
sion of the Declaration of Helsinki.
Statistics
The 95% confidence interval for the within-subject difference in a
paired case was used as a measure of statistical significance. Stu-
dent's t-test (paired, two-sided) was used to find out the exact p-
value (13).
Results
The effects of ramipril on the hormonal status of study
patients are shown in table 2. Ramipril decreased the
value of free thyroxine when measured with Amerlex-
MAB* (Amersham, UK): The mean value of free thy-
roxine before medication was 17.1 pmol/1 and at the end
of medication 16.0 pmol/1. The mean within-subject dif-
ference was —1.10 pmol/1 with a 95% confidence in-
terval of -1.87 pmol/1 0.33 pmol/1 and p = 0.011
(Student's t-test). When measured with AutoDELFIA™
(Wallac, Finland) the value of free thyroxine did not
change statistically significantly, p = 0.268. Neither did
the value of free thyroxine change statistically signifi-
Tab. 1 Hormone assays: methods, manufacturers and coefficients of inter-assay variation (CV%) at
the given concentration.
Assay Method Manufacturer CV%
DELFIA: time-resolved fluoroimmunoassay;
RIA: radioimmunoassay;
IRMA: immunoradiometric assay.
a
 In-house method (see I.e. (14)).
at concentration
Follitropin
Lutropin
Prolactin
Thyrotropin
Free thyroxine
Free thyroxine
Free thyroxine
Total thyroxine
Free triiodothyronine
Parathyrin
Cortisol
Testosterone
Sex hormone binding globulin
Androstenedione
Dehydroepiandrosterone sulphate
DELFIA®
DELFIA®
AutoDELFIA™
AutoDELFIA™
Amerlex-MAB*
AutoDELFIA™
Dialysis+RIAa
DELFIA®
AutoDELFIA™
IRMA
Spectria RIA
Spectria RIA
Spectria IRMA
Extraction+RIA
RIA
Wallac
Wallac
Wallac
Wallac
Amersham
Wallac
Medix Clinical Laboratories
Wallac
Wallac
Incstar
Orion Diagnostica
Orion Diagnostica
Orion Diagnostica
Steranti Research (antiserum)
Amersham ([3H]androstenedione)
Sorin Biomedica
3.3
4.5
2.8
5.0
5.4
4.1
7.7
3.6
8.7
13.1
6.5
6.9
7.0
11.0
8.6
0.8 U/l
0.4 U/l
5.9 μg/l
3.4 mU/1
18.7 pmol/1
27.3 pmol/1
16 pmol/1
92.2 pmol/1
4. 1 pmol/1
45ng/l
836 nmol/1
21.6nmol/l
10 nmol/1
3. 8 nmol/1
5.3 μηιοΐ/ΐ
Tab. 2 Effects of ramipril on the serum hormonal status of study
patients. In follitropin, lutropin, testosterone, sex hormone binding
globulin, androstenedione and dehydroepiandrosterone sulphate
values, only males are included.
Hormone Before ramipril
treatment
After ramipril
treatment
Mean Range Mean Range
a
 mean within-subject difference;
b
 Amerlex-MAB*;
c
 AutoDELFIA™;
d
 dialysis+RIA (see I.e. (14));
e
 ρ < 0.05;
f
 non-significant.
Mean
Follitropin
Lutropin
Prolactin
Thyrotropin
Free thyroxineb
Free thyroxinec
Free thyroxined
Total thyroxine
Free triiodothyronine
Parathyrin
Cortisol
Testosterone
Sex hormone binding globulin
Androstenedione
Dehydroepiandrosterone sulphate
U/l
U/l
μ§/ι
mU/l
pmol/1
pmol/1
pmol/1
pmol/1
pmol/1
ng/1
nmol/1
nmol/1
nmol/1
nmol/1
μιηοΐ/ΐ
4.4
3.6
7.1
1.9
17.1
12.2
13.5
113
5.9
36
465
18
36
5.8
6.8
1.7 -6.7
1.6 -5.9
4.0 -11.0
0.8 -3.2
12.3-22.5
9.4 -14.6
10 -17
74 -150
4.9 -7.7
17 -57
232 -635
9 -28
14 -56
3.2 -8.6
2.8 -11.1
4.4
3.0
6.6
1.6
16.0
12.6
13.6
110
6.3
35
472
18
36
5.6
6.8
2.2 -6.4
2.2 -4.2
3.6 -11.0
1.1 -2.4
13.5-21.9
9.3 -15.5
11 -16
98 -130
4.8 -7.7
16 -59
415 -635
6 -27
12 -58
4.1 -9.3
2.4 -13.8
-0.04
-0.55
-0.45
-0.31
-1.10"
0.35f
0.1 Of
-3.0
0.38
-0.5
6.9
0.3
0.1
-0.16
-0.09
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Fig. 1 Effects of ramipril on the free thyroxine values of indivi-
dual patients measured with Amerlex-MAB*.
cantly, ρ = 0.858, when measured with the reference
method dialysis+RIA (Medix Clinical Laboratories,
Finland) (14). Ramipril did not affect other endocrino-
logical tests. The effects of ramipril on free thyroxine of
individual patients measured with Amerlex-MAB* are
described in figure 1.
Discussion and Conclusion
The effects of angiotensin-converting enzyme inhibitors
on endocrinological tests are not well known (2). Gen-
erally, angiotensin-converting enzyme inhibitors are
shown to decrease serum aldosterone concentration and
increase serum renin concentration (2), which also ap-
plies to ramipril (9, 11). Serum insulin has been found
to decrease, increase or remain unaffected depending on
the angiotensin-converting enzyme inhibitor (2). Ac-
cording to earlier studies, angiotensin-converting en-
zyme inhibitors do not affect the concentration of serum
cortisol, catecholamines and antidiuretic hormone (2).
Similarly, during ramipril treatment, the level of insulin
secretion (12), cortisol, catecholamines and vasopressin
(9) have been reported to remain unaffected.
In the present study, the effects of ramipril on 13 endo-
crinological tests were examined. No major endocrino-
logical effects were found. Ramipril did not affect serum
cortisol concentration, which is in line with the findings
of Crazier and co-workers (9). Neither did ramipril have
statistically significant effects on serum follitropin,
lutropin, prolactin, thyrotropin, total thyroxine, free tri-
iodothyronine, parathyrin, testosterone, sex hormone
binding globulin, androstenedione or dehydroepian-
drosterone sulphate concentrations.
However, serum free thyroxine decreased from the mean
concentration of 17.1 pmol/1 to the mean concentration
of 16.0 pmol/1 during ramipril treatment when measured
with Amerlex-MAB*, which was the standard free
thyroxine assay in our laboratory during the study. As
the specimens were reanalyzed with the new Auto-
DELFIA™ assay, no effect of ramipril was detected.
Whenever an unexpected drug effect on a laboratory test
is found, it is essential to assess the nature of the effect
as analytical or biological. A biological effect causes a
real increase or decrease of a biochemical component
whereas an analytical effect is associated only with the
method used in measuring. The minimal evidence
needed for this classification requires at least two assays
based on different methodological principles. To be cer-
tain about the nature of the effect, the specimens were
reanalyzed using the reference method for free thyrox-
ine, dialysis+RIA (14). The results of the dialysis+RIA
were parallel with the AutoDELFIA™, i. e., no effect of
ramipril on free thyroxine concentration was detected.
Accordingly, the decreasing effect of ramipril on free
thyroxine was associated with the Amerlex-MAB* but
neither with the AutoDELFIA™ nor with dialysis+RIA.
The decreasing effect of ramipril on free thyroxine was
therefore concluded to be analytical.
Free thyroxine immunoassays have been strongly criti-
cized because of the misleading diagnostic results they
often yield due to abnormal serum concentrations of al-
bumin or other proteins, antibodies or inhibitors of hor-
mone binding (15, 16). Recently, Van Blerk and cowork-
ers (17) compared four radioisotope immunoassays of
free thyroxine and they evaluated the performance of
Amerlex-MAB* free thyroxine as excellent. Endogenous
albumin, however, was found to interfere with the
method and have weak positive correlation with free thy-
roxine results. According to our measurements, ramipril
did not affect the concentration of serum albumin (data
not shown) and therefore albumin could not be the com-
ponent interfering with the Amerlex-MAB* free thyrox-
ine in this study. The mechanism of the effect is still
unknown. All the same, the AutoDELFIA™ free thyrox-
ine assay based on the back-titration principle was less
sensitive to the interfering components in the specimens.
In Turku University Central Hospital we use a compu-
terized system for managing patient medication data,
laboratory data and drug-laboratory interference data
(18-20). Utilizing this system, we found that 20% of
the patients tested for free thyroxine in our hospital were
treated with an angiotensin-converting enzyme inhibitor.
In the light of this finding and the fact that the Amerlex-
MAB* assay is widely and commonly used, the effect of
ramipril or possibly all angiotensin-converting enzyme
inhibitors on free thyroxine is probably quite a common
problem in laboratories. Even though the decrease in
free thyroxine was slight and none of the patients in this
study was misclassified as hypothyroid, attention should
be paid to this problem, because misclassification of hy-
perthyroid patients as normal or normal patients as hy-
pothyroid may occur in borderline cases.
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